Ravi Jasuja
Co-Founder & Chief Scientific Officer XYone Therapeutics
Seminars
Tuesday 13th October 2026
Unlocking MUC1-C for ADC Therapy: Translational Innovation of XYA01/02 from Preclinical Validation to Clinical Forefront
12:00 pm
- Contextualizing suboptimal MUC1-N targeting properties to demonstrate benefits to MUC1-C subunit as an ADC target
- Exploring preclinical PDX safety and efficacy for XYA01/02 leading to NCI NExT program selection and IND enabling development
- Evaluating XYA01/02 trial design positioning for differentiated impact across MUC1-C-expressing epithelial carcinomas versus existing anti-MUC1 ADCs
